Scarica l'app Stockscreener
22.24
0.23%
0.05
Dopo l'orario di chiusura:
22.15
-0.09
-0.40%
Precedente Chiudi:
$22.19
Aprire:
$22.04
Volume 24 ore:
2.42M
Relative Volume:
3.29
Capitalizzazione di mercato:
$1.34B
Reddito:
$688.00K
Utile/perdita netta:
$-170.19M
Rapporto P/E:
-7.5135
EPS:
-2.96
Flusso di cassa netto:
$-154.68M
1 W Prestazione:
+5.05%
1M Prestazione:
+50.07%
6M Prestazione:
+79.07%
1 anno Prestazione:
-31.29%
Intervallo 1D:
$21.82
$23.49
Intervallo di 1 settimana:
$18.12
$23.49
Portata 52W:
$10.91
$40.26
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Nome
Spyre Therapeutics Inc
Settore
Industria
Telefono
(617) 651-5940
Indirizzo
221 CRESCENT STREET, WALTHAM
Confronta SYRE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
22.24 | 1.27B | 688.00K | -170.19M | -154.68M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-26 | Iniziato | Deutsche Bank | Buy |
| 2025-04-08 | Iniziato | Leerink Partners | Outperform |
| 2025-03-18 | Iniziato | Wolfe Research | Outperform |
| 2024-09-04 | Iniziato | Wedbush | Outperform |
| 2024-07-16 | Iniziato | Evercore ISI | Outperform |
| 2024-05-02 | Iniziato | Robert W. Baird | Outperform |
| 2024-03-01 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-12-11 | Iniziato | Guggenheim | Buy |
| 2023-12-11 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2019-03-21 | Iniziato | JP Morgan | Overweight |
| 2018-09-04 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-04-24 | Iniziato | Evercore ISI | Outperform |
| 2018-03-14 | Reiterato | Needham | Buy |
Mostra tutto
Spyre Therapeutics Inc Borsa (SYRE) Ultime notizie
Best data tools to analyze Spyre Therapeutics Inc. stockJuly 2025 Intraday Action & Short-Term Trading Alerts - newser.com
Q1 Earnings Forecast for SYRE Issued By Leerink Partnrs - Defense World
Spyre Therapeutics Closes $316.2 Million Public Offering - MarketScreener
Spyre Therapeutics Announces Public Stock Offering - TipRanks
Spyre Therapeutics Closes $316.2 Million Public Offering of Common Stock - Quiver Quantitative
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million - The Manila Times
$316.2M Raised — Spyre Therapeutics Closes 17.09M-Share Public Offering, Underwriters Exercised - Stock Titan
Will Spyre Therapeutics Inc. stock recover faster than peersQuarterly Profit Summary & Detailed Earnings Play Strategies - newser.com
Will Spyre Therapeutics Inc. stock deliver strong dividend growth2025 Momentum Check & Stock Portfolio Risk Management - newser.com
What sentiment indicators say about Spyre Therapeutics Inc. stockQuarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Sees Strong Trading Volume on Analyst Upgrade - Defense World
Spyre Therapeutics (SYRE): Assessing Valuation Following Major Equity Offering and Share Price Surge - Yahoo Finance
Spyre Therapeutics Stock Rises 11% After $275 Mln Public Offering Pricing - Nasdaq
Spyre Therapeutics rises after $275 mln equity raise - TradingView
Spyre Therapeutics IncExpects $486.2 million in cash and equivalents as of Sept 30, 2025SEC filing - MarketScreener
Spyre Therapeutics Prices $275 Million Share Offering - MarketScreener
Spyre Therapeutics (NASDAQ:SYRE) Rating Increased to Hold at Wall Street Zen - Defense World
SYRE Stock Offering Priced Below Recent Closing - GuruFocus
Spyre Therapeutics prices public offering at $18.50 per share - Investing.com
Spyre Therapeutics announces pricing of $275 million public offering of common stock - MarketScreener
$275M Offering — Spyre Therapeutics Prices 14.86M Shares for IBD Biotech - Stock Titan
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock - GlobeNewswire Inc.
Spyre Therapeutics Launches Public Offering - MarketScreener
Spyre Therapeutics announces public offering of common stock and pre-funded warrants - MSN
Spyre Therapeutics announces common stock offering, no amount given - TipRanks
Spyre Therapeutics falls after stock offering launch - TradingView
Spyre Therapeutics announces common stock offering - Investing.com India
Spyre Therapeutics Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Spyre Therapeutics to Offer Common Stock & Pre-Funded Warrants; 30-Day Underwriter Option - Stock Titan
Using Python tools to backtest Spyre Therapeutics Inc. strategiesJuly 2025 Trade Ideas & Real-Time Market Sentiment Alerts - newser.com
Will Spyre Therapeutics Inc. stock pay special dividendsNew Guidance & Accurate Buy Signal Notifications - newser.com
Can Spyre Therapeutics Inc. stock sustain free cash flow growth2025 Major Catalysts & Entry Point Confirmation Signals - newser.com
Why Spyre Therapeutics Inc. stock is a value investor pickQuarterly Trade Review & High Win Rate Trade Tips - newser.com
Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 5%Here's Why - MarketBeat
A Fresh Look at Spyre Therapeutics (SYRE) Valuation Following Encouraging SPY002 Clinical Data and Pipeline Advances - Sahm
Analyzing Spyre Therapeutics Inc. with risk reward ratio charts2025 Trading Recap & Stock Portfolio Risk Control - newser.com
How to integrate Spyre Therapeutics Inc. into portfolio analysis toolsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Is Spyre Therapeutics Inc. a candidate for recovery playWeekly Trend Summary & Community Trade Idea Sharing Platform - newser.com
Custom strategy builders for tracking Spyre Therapeutics Inc.July 2025 Opening Moves & Low Risk Investment Opportunities - newser.com
Spyre Therapeutics' (SYRE) Sell (D-) Rating Reiterated at Weiss Ratings - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Shares Up 8.9%What's Next? - MarketBeat
Should Positive Early IBD Trial Results and Combination Data Prompt Action From Spyre Therapeutics (SYRE) Investors? - Sahm
Spyre Therapeutics (NASDAQ:SYRE) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Published on: 2025-10-06 01:19:10 - newser.com
Spyre Therapeutics (SYRE) Highlights Progress at European Gastro - GuruFocus
Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress - Quiver Quantitative
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 - The Manila Times
6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior - Stock Titan
Spyre Therapeutics Inc. stock volume spike explainedWeekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Tools to monitor Spyre Therapeutics Inc. recovery probability2025 Stock Rankings & Smart Money Movement Tracker - newser.com
Spyre Therapeutics Inc. stock daily chart insightsEarnings Performance Report & Safe Capital Growth Trade Ideas - newser.com
Spyre Therapeutics Inc Azioni (SYRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Spyre Therapeutics Inc Azioni (SYRE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Albers Jeffrey W. | Director |
Nov 06 '24 |
Sale |
36.76 |
6,700 |
246,313 |
27,360 |
| Albers Jeffrey W. | Director |
Oct 25 '24 |
Sale |
36.43 |
300 |
10,929 |
34,060 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):